Hyperthyroidism and Graves Disease

Hyperthyroidism represents a clinical and biochemical syndrome of excessive thyroid hormone production and action, characterized by elevated free T4 (thyroxine) and/or free T3 (triiodothyronine) with suppressed thyroid-stimulating hormone (TSH). Graves disease is the most common cause of hyperthyroidism in iodine-sufficient regions (70-90% of cases), resulting from autoimmune production of thyroid-stimulating immunoglobulins that activate the TSH receptor on thyroid follicular cells. The disease affects approximately 1-2% of the population worldwide, with a female-to-male predominance of 5-10:1, peak incidence between ages 30-50, though it may occur at any age including children and the elderly. Graves disease carries significant clinical importance due to its potential for acute life-threatening complications (thyroid storm), cardiovascular consequences (atrial fibrillation), and bone metabolism effects, making its recognition and management essential for clinical practice and high-yield for board examinations.

The fundamental pathophysiology of Graves disease involves a loss of immune tolerance to thyroid autoantigens, culminating in T-cell and B-cell mediated autoimmunity against the TSH receptor and other thyroid-specific proteins.

In genetically predisposed individuals (HLA-DR3 and HLA-B8 associations), environmental triggers (infection, iodine exposure, stress, pregnancy, medications) break immune tolerance and activate autoreactive B cells to produce TSH receptor antibodies (TRAb), specifically immunoglobulin G (IgG) TSH receptor agonists. These TSI bind directly to the TSH receptor on thyroid follicular cells with nanomolar affinity and activate the receptor independently of TSH, bypassing normal pituitary feedback regulation. This constitutive receptor activation stimulates the adenylyl cyclase-cAMP second messenger pathway and phospholipase C-inositol 1,4,5-trisphosphate signaling, leading to increased intracellular calcium and kinase C activation. Unlike TSH binding, which is transient and feedback-regulated, TSI binding is persistent, causing uncontrolled thyroid hormone synthesis and secretion. The pathognomonic consequence is dissociation between TSH (suppressed by excess thyroid hormone) and thyroid hormone levels (elevated due to TSI drive)—this is diagnostic and distinguishes Graves disease from secondary hyperthyroidism.

TSI-mediated receptor stimulation increases expression and activity of sodium-iodide symporter (NIS), the rate-limiting pump responsible for thyroidal iodine uptake from serum. This upregulation dramatically increases thyroid iodine avidity and incorporation into thyroglobulin, increasing thyroid peroxidase (TPO) activity and organification of iodine into T3 and T4. Additionally, TSI signaling increases thyroglobulin proteolysis and hormone secretion, accelerating the rate of hormone release into circulation. The thyroid gland becomes hyperplastic and hyperactive, resulting in increased blood flow, growth, and uniform enlargement (diffuse non-nodular goiter). This increased metabolic activity is detectable on radioactive iodine uptake scanning and thyroid technetium scans as dramatically elevated uptake, distinguishing Graves disease from thyroiditis (low uptake) or factitious hyperthyroidism (suppressed uptake).

A subset of patients develop Graves ophthalmopathy (GO) and Graves dermopathy due to cross-reactive immune responses against TSH receptor-expressing cells in orbital fibroblasts and skin fibroblasts. T-cell activated B cells and plasma cells infiltrate orbital tissues, producing anti-TSH receptor and anti-TPO antibodies locally. This triggers IL-6 and TNF-α production, fibroblast hyaluronic acid synthesis, and differentiation into myofibroblasts and adipocytes, causing expansion of orbital fat and extraocular muscle enlargement. The pathophysiology is NOT simply from elevated thyroid hormone but from direct tissue-specific autoimmunity, explaining why GO can persist or worsen after achieving euthyroidism and why it is more prevalent in smokers (who have enhanced orbital fibroblast TSH receptor expression). Similarly, pretibial myxedema (dermopathy) reflects fibroblast infiltration and hyaluronic acid deposition in dermis and subcutis.

The dramatically elevated circulating free T4 and T3 increase metabolic rate, enhance tissue sensitivity to catecholamines, and drive hypermetabolic manifestations. Thyroid hormones increase β-adrenergic receptor expression on heart, adipose tissue, and skeletal muscle while enhancing tissue responsiveness to norepinephrine. This explains the characteristic adrenergic symptoms (tachycardia, tremor, anxiety, heat intolerance) even though absolute circulating catecholamine levels are normal—the tissues are hypersensitive. T3 increases myocardial contractility and decreases systemic vascular resistance, leading to high cardiac output state (elevated systolic blood pressure, widened pulse pressure, bounding pulses). Thyroid hormones increase oxygen consumption and metabolic heat production, causing thermoregulation abnormality with preference for cooler temperatures. At the skeletal level, excess thyroid hormone increases bone resorption via osteoclast activation (mediated by IL-6) and decreases bone formation, resulting in net bone loss and increased fracture risk—a critical long-term complication.

Graves disease is an organ-specific autoimmune disorder caused by TSH receptor-stimulating antibodies (TSI/TRAb). Genetic predisposition includes HLA-DR3, HLA-B8, and PTPN22 gene polymorphisms; environmental triggers include bacterial and viral infections (Yersinia, Borrelia, EBV, enterovirus), iodine supplementation (excessive dietary iodine increases autoimmunity risk), pregnancy and postpartum state (immune reconstitution), estrogen (explains 5-10:1 female predominance), medications (interferon-α, interleukin-2, checkpoint immunotherapy), and psychosocial stress. Female sex, younger age at onset, and family history of autoimmune thyroid disease are strong risk factors.

Long-standing iodine deficiency followed by adequate iodine repletion permits autonomous thyroid follicular cells (which developed TSH-independent function during iodine scarcity) to increase hormone production excessively. Multiple nodules with independent TSH receptor mutations (gain-of-function) autonomously produce thyroid hormone without feedback suppression. Occurs in older patients with long-standing goiter; radioactive iodine uptake is heterogeneous, with high uptake in autonomous nodules and suppressed uptake in surrounding normal thyroid.

Single TSH receptor mutation (TSHR or GNAS mutations) in a thyroid follicular cell creates a clone with constitutive receptor activation, leading to autonomous thyroid hormone production from that nodule only. Radioactive iodine uptake is concentrated in the nodule with suppressed uptake elsewhere. Often presents with lower degree of hyperthyroidism than Graves disease.

Viral infection (subacute thyroiditis) or autoimmune infiltration causes thyroid inflammation, releasing preformed thyroid hormone from damaged follicles. This produces transient hyperthyroidism (weeks to months) followed by hypothyroidism as hormone stores deplete and inflammation resolves. Critical diagnostic distinction: radioactive iodine uptake is LOW or absent (follicles are damaged, not hyperactive), whereas Graves disease and toxic nodules show HIGH uptake.

Intentional or accidental thyroid hormone overdose (fictitious thyroiditis) produces elevated thyroid hormones with suppressed radioactive iodine uptake and suppressed endogenous TSH—the thyroid is biochemically normal and not producing hormone. Often seen in patients with eating disorders or health anxiety.

TSH-producing adenomas (rare) cause secondary hyperthyroidism with inappropriately normal or elevated TSH (not suppressed). Trophoblastic diseases and germ cell tumors secrete human chorionic gonadotropin (hCG), which has weak TSH-like activity on TSH receptor, causing thyroid hormone elevation with suppressed endogenous TSH. Gestational thyrotoxicosis from very high hCG in early pregnancy presents with suppressed TSH and mild T4 elevation, typically self-limited.

Patients characteristically present with palpitations (awareness of rapid heartbeat, often with irregular rhythm if atrial fibrillation develops), a hallmark symptom reflecting both tachycardia and increased cardiac contractility. Heat intolerance and excessive diaphoresis (inappropriate sweating in cool environments) result from increased metabolic heat production and resetting of the hypothalamic thermostat to a higher setpoint. Tremor, typically fine and rapid (high-frequency), occurs due to enhanced tissue responsiveness to catecholamines and increased firing rate of motor neurons; it is most prominent distally in the fingers and evident when holding a sheet of paper. Weight loss despite good appetite is characteristic (due to increased basal metabolic rate exceeding caloric intake), distinguishing it from cancer cachexia; some patients experience polyphagia (increased appetite) but still lose weight.

Patients commonly report anxiety, nervousness, and emotional lability, often severe enough to prompt psychiatric consultation; these reflect both direct central nervous system effects of thyroid hormone and peripheral catecholamine hypersensitivity. Insomnia is typical, with patients unable to fall asleep despite fatigue. Difficulty concentrating and memory complaints are frequent, though overt cognitive impairment is unusual. Some patients present with thyroid storm with psychosis, confusion, or acute delirium, especially if precipitated by acute stressor.

Occurs in 25-50% of Graves patients to varying degrees. Classic exophthalmos (proptosis) results from expansion of orbital fat and extraocular muscle enlargement; measure using Hertel exophthalmometer (normal <21 mm). Lid retraction is a highly characteristic sign due to increased sympathetic tone to Müller's muscle (upper lid retraction, "lid stare") and inferior rectus muscle overaction (lower lid lag when eyes look downward—"lid lag sign"). Lid lag is assessed by having patient follow examiner's finger slowly downward; delay in upper lid descent is positive sign. Patients may experience gritty sensation, foreign body sensation, eye pain, and diplopia (from extraocular muscle weakness, most commonly affecting vertical gaze). Severe cases develop ophthalmoplegia, corneal ulceration from inability to close lids (exposure keratopathy), and compressive optic neuropathy with vision loss. Smoking increases risk and severity of ophthalmopathy 7-fold.

Physical examination typically reveals tachycardia (even at rest during sleep), systolic hypertension with widened pulse pressure (from decreased diastolic pressure due to decreased peripheral vascular resistance), bounding pulses, and hyperactive precordium with hyperdynamic apical impulse. Atrial fibrillation occurs in 10-15% of patients with hyperthyroidism, more common in older patients and those with underlying cardiac disease; this significantly increases stroke risk. A characteristic systolic flow murmur at the left sternal border or apex may be heard due to high cardiac output across the aortic or mitral valve. Heart rate typically exceeds 90-100 bpm at rest and does not slow appropriately with sleep or relaxation; the sleeping pulse rate is notably elevated and helps distinguish thyroid disease from anxiety. Thyroid hormone increases myocardial oxygen demand, potentially precipitating angina pectoris in patients with coronary artery disease.

Patients are often warm and moist to touch with warm, velvety skin. Fine hair and occasionally alopecia may occur. Weakness and fatigue are paradoxically common (despite high metabolic rate) and reflect protein catabolism, myopathy from thyroid hormone excess, and poor sleep. Thyroid hormone-induced proximal muscle weakness results from myopathy and affects hip and shoulder girdle preferentially; some patients develop rhabdomyolysis in severe disease. Osteoporosis and increased fracture risk develop from increased bone resorption; this may not be clinically evident acutely but is important long-term consequence.

Patients frequently present with diarrhea (increased intestinal motility from enhanced catecholamine sensitivity), though some experience constipation. Nausea, vomiting, and loss of appetite may occur, particularly in severe hyperthyroidism or thyroid storm. Hepatosplenomegaly occurs occasionally. Thyroid hormone increases cholesterol turnover and decreases LDL, leading to characteristically low cholesterol levels despite high metabolic rate.

Diffuse goiter (uniform thyroid enlargement without nodules) is present in majority of Graves patients. The thyroid gland is typically firm, non-tender (unlike thyroiditis), hypervascular, and may exhibit a palpable thrill or audible bruit on auscultation from increased blood flow—these findings are highly suggestive of Graves disease. Pretibial myxedema (Graves dermopathy)—"thyroid acropathy"—is rare but pathognomonic; presents as waxy, indurated skin thickening over anterior shins and dorsum of feet, usually in patients with severe ophthalmopathy and high titers of TSH receptor antibodies.

Apathetic thyrotoxicosis occurs in elderly patients who may present with primarily cardiovascular findings (heart failure, atrial fibrillation, angina) or weight loss, with minimal hyperadrenergic symptoms; this is easily missed on initial evaluation. Thyroid storm is an acute, life-threatening exacerbation characterized by high fever (>38.5°C, often 39-41°C), marked tachycardia (often >140 bpm), mental status changes (confusion, psychosis, coma), gastrointestinal symptoms (severe nausea, vomiting, diarrhea, jaundice), and cardiovascular collapse; precipitants include infection, surgery, trauma, radioactive iodine administration, or abrupt antithyroid drug discontinuation.

Diagnosis of hyperthyroidism begins with suppressed TSH (<0.1 mIU/L) as the most sensitive initial screening test. When TSH is suppressed, measure free T4 and free T3 to confirm overt hyperthyroidism. Most patients with Graves disease present with elevated free T4 and/or elevated free T3 (reference ranges: free T4 0.8-1.8 ng/dL, free T3 2.3-4.2 pg/mL). Approximately 5% of Graves patients present with T3 thyrotoxicosis (elevated T3 with normal free T4), particularly early in disease; these patients must not be missed. The combination of suppressed TSH + elevated free thyroid hormones confirms overt hyperthyroidism; low-normal or undetectable TSH with high-normal thyroid hormones indicates subclinical hyperthyroidism.

TSH receptor antibody (TRAb) testing is the single most specific test for Graves disease, with sensitivity and specificity both >90% in overt disease. Two methodologies: (1) TBII (thyroid binding inhibitory immunoglobulin) assay, which measures ability of patient IgG to inhibit TSH binding to TSH receptor; (2) **TSI (thyroid-stimulating immunoglo

Immediate stabilisation (thyroid storm — Burch-Wartofsky score supports the diagnosis): per the American Thyroid Association (ATA) 2016 hyperthyroidism guideline, treat in a specific order: